Synapto is an early-stage medical technology company transforming Alzheimer's Disease screening through portable EEG and Machine Learning.
Our platform extracts complex mathematical characteristics from a patient’s brainwaves, and by engaging machine learning, decides whether that particular brainwave has signatures of neurodegeneration or is healthy.
A portable Electroencephalogram records highly sensitive electrical signals in the brain, which can then be inspected using novel methods of analyses. Recordings like these then allow machine learning models to predict the severity and progression of the disease. For research, Synapto is utilizing portable EEG from OpenBCI and other sources, making our platform unique in that it is more affordable and accessible than current EEG diagnostic measures.
Synapto’s project serves as a prime example of how tomorrow’s bioengineers are working today to find solutions to some of the most significant health challenges our society faces.
This represents a monumental achievement, not simply for the engineering community, but for the wider world of human health research.
I think the device is unique and will prove to be the first line of testing in the future for detection of Alzheimer disease.